Clinical Trial Search

Primary: Mean Intestinal Chemosensitivity to Lipids Perfusion — 0.22; 0.36; 0.55; 0.65 score on a scale — p=0.06

Primary: Self-Report of Adequate Relief of Dyspepsia (Yes/No) For at Least 50% of Weeks 3 -12 of Treatment — 53; 38; 40 percentage of participants — p=0.05

Primary: Change From Baseline in DYSPEPSIA RELATED HEALTH SCALE (DRHS) — 73.72; 65.31; 71.85; 64.89 units on a scale

Primary: Pain Scores on the 100-millimeter Visual Analog Scale (VAS) at 1 Hour After Treatment — 17; 19 millimeter — p=0.6

Primary: Change From Baseline in Reflux Disease Questionnaire (RDQ) Scores for the GERD Dimension — -1.27; -1.06 score on a scale — p=<0.0001

Primary: Measure: Number of Participants With no Heartburn (Post Treatment) Following Consumption of Heartburn-inducing Meal — 0; 2; 1; 0 participants

Primary: Percentage of Participants With Satisfactory Relief of Non-ulcer Dyspepsia Symptoms — 71; 34; 82; 56 percentage of participants

Primary: Maximum Satiation — 892.5; 951.75; 655.5; 892.5 mL — p=0.12

Primary: Subjective Symptom Improvement Rate — 75.7; 73.5; 68.6; 65.3 percentage of participants

Primary: Determination of Median Time to Sustained Partial Response as Defined by Reduction in Likert Severity Scale Used to Assess Pain Associated With Heartburn in the Patient…

Primary: Gastroesophageal pH — 7.3; 6.6; 3.7; 4.9 percent time ph < 4 in 24 hrs

Primary: Number of Participants in Each Level of Wheeze Control — 18; 11; 9 Participants

Primary: Coefficient of Fat Absorption (CFA) — 88.1; 89.5 percentage of fat intake